Michigan Alzheimer's Disease Research Center

密歇根阿尔茨海默病研究中心

• 批准号: 10473806
• 负责人: Henry L Paulson
• 金额: $ 307.59万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-01 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10473806
• 关键词: Address; Affect; African American; Aging; Alzheimer' s Disease; Alzheimer' s disease related dementia; Alzheimer' s disease therapy; American; Amyloid beta-Protein; Award; Biological Markers; Black American; Black race; Capsicum; Centers of Research Excellence; Clinical; Cognition; Collaborations; Communities; Dementia; Development; Diagnosis; Diagnostic; Disclosure; Disease; Education and Outreach; Elderly; Ensure; Environment; Foundations; Funding; Health; Health Disparities Research; Health Professional; Heterogeneity; Hispanic; Knowledge; Latino; Lead; Lewy Body Dementia; Light; Link; Longitudinal cohort; Mentors; Michigan; Modification; Molecular Profiling; Multi-Institutional Clinical Trial; Nerve Degeneration; Nonpharmacologic Therapy; Parkinson Disease; Participant; Peripheral; Population Research; Protein-Folding Disease; Research; Research Subjects; Research Support; Resources; Risk; Scientist; Site; Students; Therapeutic; Training; United States; Universities; Vascular Dementia; Work; aging demography; brain dysfunction; contextual factors; disorder risk; education research; experience; frontotemporal lobar dementia-amyotrophic lateral sclerosis; gene environment interaction; health disparity; improved; innovation; molecular imaging; neuroimaging marker; next generation; novel; novel diagnostics; novel marker; novel therapeutic intervention; outreach; programs; racial diversity; recruit; symposium; training opportunity; translational neuroscience

ABSTRACT – OVERALL Four years ago the Michigan ADRC (MADRC) was established as a new consortium linking the three major research universities in Michigan: University of Michigan, Michigan State University, and Wayne State University. Serving the entire state of Michigan, the new MADRC achieved its milestones in wide-ranging activities and research that emphasized a central theme: to identify, understand and treat the myriad non-β- amyloid contributions to brain dysfunction and degeneration in Alzheimer’s disease and related dementias (ADRD). With continued NIA support, the MADRC proposes to maintain this central theme because it captures the diverse expertise of our dementia scientists, sheds light on ADRD heterogeneity, and reflects the experience of the racially diverse pool of research participants engaged in MADRC-sponsored studies. To achieve its objectives, the MADRC has four major aims: 1) Catalyze and perform research of the highest impact in ADRD; 2) Promote regional efforts to understand, diagnose and treat the full spectrum of dementias through collaborative scientific and outreach efforts; 3) Provide training and research opportunities for health care professionals, scientists, and students in ADRD through innovative educational and mentoring programs; and 4) Collaborate with other ADRCs, the NACC, NCRAD, and other multi-center efforts to lead the field in developing new diagnostic and therapeutic interventions for these devastating diseases. The integrated efforts of seven Cores, including new Neuroimaging and Biomarker cores, will support a wide range of basic, clinical, translational and health disparities research advancing the field toward: improved understanding of disease mechanisms; more precise disease identification across the dementia spectrum; development of novel biomarkers; increased knowledge of the basis for health disparities that disproportionately affect Black Americans; development of non-pharmacological therapies; and the identification and modification of disease risks. The Research Education Component (REC) will serve as the centerpiece of innovative training opportunities spanning all the Cores, and a new Leaders Initiative will support and promote a diverse group of next-generation leaders in dementia research. Benefitting from the outstanding resources of all three universities and strong multi-institutional support, the MADRC is poised to make new discoveries, educate the public, and train next-generation leaders as we seek to achieve the milestones set forth in the National Alzheimer’s Project Act.

摘要-总体 四年前，密歇根州ADRC（MADRC）成立，作为一个新的财团连接三大 密歇根州的研究型大学：密歇根大学、密歇根州立大学和韦恩州立大学 大学新的MADRC服务于整个密歇根州，在广泛的领域取得了里程碑式的成就。 活动和研究，强调一个中心主题：识别，理解和治疗无数的非β- 淀粉样蛋白在阿尔茨海默病和相关痴呆中对脑功能障碍和变性的作用 （ADRD）.在NIA的持续支持下，MADRC建议保持这一中心主题，因为它抓住了 我们的痴呆症科学家的不同专业知识，揭示了ADRD的异质性，并反映了 参与MADRC赞助研究的不同种族研究参与者的经验。到 为了实现其目标，MADRC有四个主要目标：1）催化和执行最高水平的研究 2）促进区域努力，以了解、诊断和治疗各种痴呆症 通过协作性的科学和外联努力; 3）提供卫生培训和研究机会 通过创新的教育和指导计划，护理专业人员，科学家和ADRD学生; 4）与其他ADRC、NACC、NCRAD和其他多中心努力合作，在以下方面引领该领域： 为这些毁灭性疾病开发新的诊断和治疗干预措施。的综合努力 七个核心，包括新的神经影像和生物标志物核心，将支持广泛的基础，临床， 翻译和健康差异研究推进该领域朝着：提高对疾病的理解 机制;更精确的疾病识别整个痴呆症谱;开发新的 生物标志物;增加对不成比例地影响黑人的健康差异的基础的了解 美国人;非药物治疗的发展;以及疾病的识别和改变 风险研究教育部分（REC）将作为创新培训的核心 机会跨越所有的核心，一个新的领导人倡议将支持和促进一个多元化的群体， 痴呆症研究的下一代领导者。得益于这三家公司的优秀资源 大学和强大的多机构支持，MADRC准备作出新的发现，教育 公众，并培养下一代领导人，因为我们寻求实现国家 老年痴呆症项目法案